John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, shares his highlights and discusses the importance of the 2nd European CAR T-Cell Meeting. Prof. Gribben highlights the progress observed in Europe in the last year, the use of CAR T-cells in solid tumors and gene editing. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.